Work done by EuroscreenFast as part of its fee-for-service activities has been recently published in the British Journal of Pharmacology

A recent publication by Rubio-Beltrán et al. in the British Journal of Pharmacology investigates the in vitro and in vivo pharmacological properties of lasmiditan, a 5-HT1F receptor agonist developed as an antimigraine drug, in comparison with sumatriptan which acts as a 5-HT1B/1D agonist.
The study compares binding and second messanger activities of lasmiditan and other serotoninergic agonists at the recombinant human 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B and 5-HT7 receptors. This in vitro work on recombinant receptors was done at EuroscreenFast, and we are pleased to have contributed to this high quality publication which you can find here.